SEQ ID NO: 506 of Patent CN110785183A

General Information


DRACP ID  DRACP06789

Peptide Name   SEQ ID NO: 506 of Patent CN110785183A

Sequence  RYVFPLPYL

Sequence Length  9

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Cancer targeted peptides Immunotherapeutic peptides



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  HLA-B*24

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C60H86N12O12

Absent amino acids  ACDEGHIKMNQSTW

Common amino acids  LPY

Mass  131028

Pl  9.17

Basic residues  1

Acidic residues  0

Hydrophobic residues  4

Net charge  1

Boman Index  166

Hydrophobicity  47.78

Aliphatic Index  118.89

Half Life 
  Mammalian: 4.4 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  2980

Absorbance 280nm  372.5

Polar residues  2

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID CN110785183A

Patent Title  Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.